WANDA WHIDDON: Open Payments
NPI 1093480840 · MOBILE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,263 in 54 payments from 13 companies in 2025. Trend: 2023 $2,038 · 2024 $911 · 2025 $1,263
Food & beverage: $1,263
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 11 | $259 |
| Alkermes, Inc. | 8 | $184 |
| Neurocrine BioSciences, Inc. | 7 | $156 |
| Corium, LLC | 8 | $139 |
| E.R. Squibb & Sons, L.L.C. | 1 | $123 |
| Vanda Pharmaceuticals Inc. | 4 | $118 |
| Axsome Therapeutics, Inc. | 4 | $73 |
| Teva Pharmaceuticals USA, Inc. | 3 | $71 |
| Janssen Pharmaceuticals, Inc | 2 | $44 |
| Lundbeck LLC | 2 | $35 |
Products named: REXULTI, ARISTADA, INGREZZA, Azstarys, COBENFY, FANAPT, Auvelity, UZEDY.
Industry payments across AL — which companies pay providers there.
